ArticleNeurology and therapy2026
Long-Term Real-World Outcomes Among Patients with Major Depressive Disorder with Anxiety-Related Diagnosis Taking Brexpiprazole as Augmentation with Antidepressant Treatment.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with major depressive disorder (MDD) often experience comorbid anxiety diagnoses, associated with poorer treatment responses. Although adjunctive therapies show efficacy in patients with comorbid anxiety in randomized controlled trials, evidence supporting their effectiveness in real-world settings remains limited. This study characterized real-world clinical outcomes in patients with MDD with and without evidence of an anxiety-related diagnosis who were treated with adjunctive brexpiprazole.
methodsThis analysis considered subsets of patients with MDD with and without comorbid anxiety from a retrospective study of linked electronic medical records and claims data. Patients with MDD using adjunctive brexpiprazole were included if they had ≥ 12 months of continuous data before and after brexpiprazole initiation. Anxiety status was determined from clinical records or claims diagnoses. Clinical outcomes included depressive symptom severity [9-item Patient Health Questionnaire (PHQ-9)] anxiety symptom severity [7-item Generalized Anxiety Disorder scale (GAD-7)] and clinician-rated improvement [Clinical Global Impression-Improvement (CGI-I)]. Changes from baseline to follow-up were analyzed separately for patients with and without anxiety-related diagnoses. Clinical improvement was further evaluated using standard thresholds for remission (PHQ-9 score < 5) and response (CGI-I score ≤ 2).
resultsAmong 1073 patients with MDD, 653 had anxiety-related diagnoses, and 420 did not. Patients with anxiety-related diagnoses had a PHQ-9 score mean change of - 2.6 (95% CI: - 3.1 to - 2.2; p < 0.001); those without evidence of an anxiety-related diagnosis had a mean change of - 3.0 (95% CI: - 3.6 to - 2.4; p < 0.001). For patients with evidence of anxiety-related diagnoses, GAD-7 scores improved with brexpiprazole (mean change: - 2.7; 95% CI: - 3.7 to - 1.7; p < 0.001). PHQ-9 remission was achieved by 17.2% and 21.4% of patients with and without evidence of anxiety-related diagnoses, and CGI-I response was observed in 18.1% and 16.2% of patients, respectively.
conclusionThis real-world study provides evidence on clinical outcomes following initiation of adjunctive brexpiprazole in adults with MDD with and without anxiety-related diagnoses. The observed improvements support the value of evaluating adjunctive therapies in patient populations that reflect routine clinical practice.
Indexed as
Identifiers
42905249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.